AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31885286 — intervention group
Group type: COMPARATOR
Intervention: Control (islets harvested in a normal medium)
Number of subjects: 0
Study 28162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Number of subjects: 71
Study 28162818 — intervention group
Group type: COMPARATOR
Intervention: No preoperative immunonutrition (Control)
Number of subjects: 71
Study 26438108 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coil group (rTMS)
Number of subjects: 36
Study 26438108 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 36
Study 22858559 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased ipilimumab
Number of subjects: 130
Study 22858559 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab
Number of subjects: 130
Study 22858559 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 130
Study 21452932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone
Number of subjects: 120
Study 21452932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy and radiotherapy
Number of subjects: 120
Study 19728936 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injections (80 mg of methylprednisolone with 3 ml of 2% plain xylocaine and 3 ml of normal saline)
Number of subjects: 50
Study 19728936 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (bed rest, non-steroidal anti-inflammatory agents, muscle relaxants, and opioids)
Number of subjects: 50
Study 17713335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP; 1,450 ppm F) dentifrice
Number of subjects: 296
Study 17713335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF; 1,450 ppm F) dentifrice
Number of subjects: 296
Study 17713335 — intervention group
Group type: COMPARATOR
Intervention: Herbal, non-fluoride placebo dentifrice
Number of subjects: 296
Study 12796224 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride or nortriptyline hydrochloride, with or without interpersonal psychotherapy
Number of subjects: 395
Study 12796224 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients (recent suicide attempt or current suicidal ideation)
Number of subjects: 395
Study 12796224 — intervention group
Group type: COMPARATOR
Intervention: Moderate-risk patients (recurrent thoughts of death)
Number of subjects: 395
Study 12796224 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients (no suicide attempt, suicidal ideation, or thoughts of death)
Number of subjects: 395
Study 10819854 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 1862
Study 10819854 — intervention group
Group type: COMPARATOR
Intervention: Early pushing
Number of subjects: 1862
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 135 mg/m2
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin doses >60 mg/m2
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin doses
Number of subjects: 287
Study 8648369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters
Number of subjects: 287
Study 1523876 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP‐virosome vaccine
Number of subjects: 77
Study 1523876 — intervention group
Group type: COMPARATOR
Intervention: HA vaccine
Number of subjects: 77
Study 6150183 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 6150183 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 30806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented coping strategies
Number of subjects: 500
Study 30806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping strategies
Number of subjects: 500
Study 30806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological well-being
Number of subjects: 500
Study 30806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of practice environment
Number of subjects: 500
Study 28010050 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of intravenous iron isomaltoside
Number of subjects: 13
Study 28010050 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusion
Number of subjects: 13
Study 25966266 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride combined with hemoperfusion
Number of subjects: 61
Study 25966266 — intervention group
Group type: COMPARATOR
Intervention: Penehyclidine hydrochloride alone (control group)
Number of subjects: 61
Study 23808948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted water immersion
Number of subjects: 208
Study 23808948 — intervention group
Group type: COMPARATOR
Intervention: Water immersion colonoscopy
Number of subjects: 208
Study 22338233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid bioartificial liver support system
Number of subjects: 12
Study 22338233 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (Control)
Number of subjects: 12
Study 19803232 — intervention group
Group type: EXPERIMENTAL
Intervention: J in three‐needle therapy
Number of subjects: 180
Study 19803232 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 180
Study 16953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey of Hope intervention (8 modules of education on mental illness, problem-solving and communication skills training, family support)
Number of subjects: 462
Study 16953007 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 462
Study 15663103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaton (Itopridi hydrochloridum)
Number of subjects: 64
Study 15663103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10788542 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH 82 300 mg/day
Number of subjects: 100
Study 10788542 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week
Number of subjects: 100
Study 9058219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (1 mg/kg)
Number of subjects: 32
Study 9058219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study 8473250 — intervention group
Group type: EXPERIMENTAL
Intervention: Active student response error correction
Number of subjects: 6
Study 8473250 — intervention group
Group type: COMPARATOR
Intervention: No-response error correction
Number of subjects: 6
Study 4037714 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of Primperan
Number of subjects: 12
Study 4037714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31127399 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulation of nifedipine (3.083 mg HPMC K15M, 29.859 mg HPMC E15LV, 3.541 mg Carbopol 974P)
Number of subjects: 10
Study 31127399 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulation of nifedipine
Number of subjects: 10
Study 31240769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight condition
Number of subjects: 320
Study 31240769 — intervention group
Group type: COMPARATOR
Intervention: Symptom frequency (daily or weekly)
Number of subjects: 320
Study 28063801 — intervention group
Group type: EXPERIMENTAL
Intervention: mid‐follicular phase recombinant LH (rLH) supplementation
Number of subjects: 49
Study 28063801 — intervention group
Group type: COMPARATOR
Intervention: urinary human chorionic gonadotrophin (uHCG) supplementation
Number of subjects: 49
Study 25213157 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-focused cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 67
Study 25213157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 67
Study 23683793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day + Guanfacine 1 mg/day (N/G)
Number of subjects: 301
Study 23683793 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day + Guanfacine placebo (N/P)
Number of subjects: 301
Study 23683793 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo + Guanfacine (P/G)
Number of subjects: 301
Study 23683793 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (P/P)
Number of subjects: 301
Study 21524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 532
Study 21524239 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 100 mg once daily
Number of subjects: 532
Study 18971892 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet patch (M)
Number of subjects: 58
Study 18971892 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (P)
Number of subjects: 58
Study 16153766 — intervention group
Group type: EXPERIMENTAL
Intervention: TiN coating at 200 W
Number of subjects: 4
Study 16153766 — intervention group
Group type: EXPERIMENTAL
Intervention: TiN coating at 500 W
Number of subjects: 4
Study 16153766 — intervention group
Group type: COMPARATOR
Intervention: Non-coated group without metal conditioner
Number of subjects: 4
Study 16153766 — intervention group
Group type: COMPARATOR
Intervention: Non-coated group with metal conditioner
Number of subjects: 4
Study 14971864 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 384
Study 11002408 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA; Tiobec) 600 mg per day for 20 days followed by 200 mg per day for 10 days
Number of subjects: 42
Study 11002408 — intervention group
Group type: COMPARATOR
Intervention: Cellulose starch 100 mg per day as placebo
Number of subjects: 42
Study 11002408 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) after switching from placebo
Number of subjects: 42
Study 9216279 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluid (W‐i.v.f.)
Number of subjects: 30
Study 9216279 — intervention group
Group type: COMPARATOR
Intervention: Room temperature intravenous fluid (RT‐i.v.f.)
Number of subjects: 30
Study 8484502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine infusion (5 mg/min for the first 2 min, then 1 mg/min for the next 18 min)
Number of subjects: 54
Study 8484502 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid administration (15 mL/kg)
Number of subjects: 54
Study 3438130 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback
Number of subjects: 42
Study 3438130 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 3438130 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-only group
Number of subjects: 42
Study 30107070 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 83
Study 30107070 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study 28187920 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged monitoring (10-day Holter-ECG monitoring at baseline, and at 3 months and 6 months)
Number of subjects: 398
Study 28187920 — intervention group
Group type: COMPARATOR
Intervention: Standard care procedures (at least 24 hours of rhythm monitoring)
Number of subjects: 398
Study 25627795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 201
Study 25627795 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 201
Study 23901264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐α (3 million IU) 3 times per week (group B)
Number of subjects: 164
Study 23901264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐γ (3 million IU) 3 times per week (group C)
Number of subjects: 164
Study 23901264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + IFN‐α and IFN‐γ (1.5 million IU of each) 3 times per week (group D)
Number of subjects: 164
Study 23901264 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 164
Study 21908960 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain used (Group B)
Number of subjects: 72
Study 21908960 — intervention group
Group type: COMPARATOR
Intervention: No suction drain used (Group A)
Number of subjects: 72
Study 17503182 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (50 mg)
Number of subjects: 51
Study 17503182 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 51
Study 17503182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16683433 — intervention group
Group type: EXPERIMENTAL
Intervention: Orion plate system
Number of subjects: 122
Study 16683433 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephir plate system
Number of subjects: 122
Study 16683433 — intervention group
Group type: EXPERIMENTAL
Intervention: Codman plate system
Number of subjects: 122
Study 14610048 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 28 days for 2 years)
Number of subjects: 1010
Study 14610048 — intervention group
Group type: COMPARATOR
Intervention: CMF (six 28-day cycles)
Number of subjects: 1010
Study 14610048 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 1010
Study 10921358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude (4300 m)
Number of subjects: 228
Study 7782031 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant a2 interferon (Roferon) 6 MU x 7 days every 3 weeks, Adriamycin 60 mg/m2 i.v. once every 3 weeks, Tamoxifen 10 mg p.o. twice daily continuously, Desferrioxamine 500 mg i.m. daily x 7 days every 3 weeks, Ascorbic acid 300 mg p.o. daily 1 hour after DFO x 7 days every 3 weeks
Number of subjects: 7
Study 7782031 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 7
Study 2236463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate maintenance doses (600 mg to 1,500 mg/day)
Number of subjects: 30
Study 2236463 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva lithium levels
Number of subjects: 30
Study 346191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent antibody method for detection of estrogen receptors
Number of subjects: 106
Study 346191 — intervention group
Group type: COMPARATOR
Intervention: Dextran-coated charcoal and sucrose gradient assay techniques
Number of subjects: 106
Study 30109474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/Quinidine (DM/Q)
Number of subjects: 14
Study 30109474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30522086 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive angiography (or computed tomography angiography as per local preference) within 5 days of randomization
Number of subjects: 1800
Study 30522086 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (with or without functional testing at clinician discretion)
Number of subjects: 1800
Study 28212135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastent thrombus less than 16%
Number of subjects: 128
Study 28212135 — intervention group
Group type: COMPARATOR
Intervention: Intrastent thrombus at least 16%
Number of subjects: 128
Study 25960116 — intervention group
Group type: EXPERIMENTAL
Intervention: PFJ-targeted exercise, education, manual-therapy and taping program
Number of subjects: 92
Study 25960116 — intervention group
Group type: COMPARATOR
Intervention: OA-education (control condition)
Number of subjects: 92
Study 23275098 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified food frequency questionnaire (FFQ)
Number of subjects: 29
Study 23275098 — intervention group
Group type: COMPARATOR
Intervention: 3-day food record (3DFR)
Number of subjects: 29
Study 21619909 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13+TIV
Number of subjects: 1160
Study 21619909 — intervention group
Group type: COMPARATOR
Intervention: Placebo+TIV
Number of subjects: 1160
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital communication
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail communication
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with telephone number
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct from trials office
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay terms for results
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Next of kin receiving results
Number of subjects: 1431
Study 18059398 — intervention group
Group type: EXPERIMENTAL
Intervention: Next of kin not receiving results
Number of subjects: 1431
Study 16468060 — intervention group
Group type: EXPERIMENTAL
Intervention: LITE (40% of maximal oxygen consumption)
Number of subjects: 47
Study 16468060 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (60% of maximal oxygen consumption)
Number of subjects: 47
Study 16468060 — intervention group
Group type: COMPARATOR
Intervention: Control (seated rest)
Number of subjects: 47
Study 12956742 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bronchoscopic bronchial brushing
Number of subjects: 63
Study 12956742 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults undergoing standard bronchoscopic sampling)
Number of subjects: 63
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg
Number of subjects: 267
Study 11022987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg vs 800 microg)
Number of subjects: 267
Study 11022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 267
Study 9433608 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust multipoint genome scans for linkage using a dense marker map
Number of subjects: 0
Study 9433608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lod‐score likelihood analyses in full pedigrees and affected relative families
Number of subjects: 0
Study 9433608 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence from more than one method
Number of subjects: 0
Study 8519374 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms.day-1) plus salbutamol (600 micrograms.day-1) (BA+CS)
Number of subjects: 55
Study 8519374 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol plus placebo (BA+PL)
Number of subjects: 55
Study 8519374 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms.day-1) plus salbutamol (600 micrograms.day-1) (BA+CS) after switching from BA+PL
Number of subjects: 55
Study 3507007 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef extended with soy isolate, soy concentrate, or soy flour (20% reconstituted soy product, 80% beef)
Number of subjects: 245
Study 3507007 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Number of subjects: 245
Study 3507007 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming usual self-selected diets
Number of subjects: 245
Study 30015405 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1148
Study 30015405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1148
Study 30015405 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1148
Study 26784110 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to four types of physical IPV in the past year
Number of subjects: 1238
Study 26784110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lagged IPV intensity
Number of subjects: 1238
Study 26784110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed effects regression model accounting for time-invariant confounding
Number of subjects: 1238
Study 24057079 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (group I) with 1 intravaginal ovule containing 30 mcg estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live bacteria) once daily for 2 weeks, then two ovules once weekly for a total of 6 months plus pelvic floor rehabilitation.
Number of subjects: 136
Study 24057079 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation (group II).
Number of subjects: 136
Study 23247908 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed IRO‐A (15 mg)
Number of subjects: 40
Study 23247908 — intervention group
Group type: COMPARATOR
Intervention: Crushed IRO (15 mg)
Number of subjects: 40
Study 20545406 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Support
Number of subjects: 35
Study 20545406 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 35
Study 18337057 — intervention group
Group type: EXPERIMENTAL
Intervention: Full effort instruction
Number of subjects: 73
Study 18337057 — intervention group
Group type: COMPARATOR
Intervention: Malingering scenario instruction
Number of subjects: 73
Study 16299090 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent prevention campaign including educational brochures and media broadcasts
Number of subjects: 237
Study 16299090 — intervention group
Group type: COMPARATOR
Intervention: Comparison with non-eye injury rates
Number of subjects: 237
Study 12455823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool exercise therapy and education
Number of subjects: 26
Study 11270999 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Number of subjects: 20